Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity

提高对结核病肺免疫的了解，建立针对粘膜免疫的多样化、创新型结核疫苗管道

• 批准号: 10068466
• 金额: $ 107.91万
• 依托单位: LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10068466
• 关键词: Improving; understanding; lung; immunity; tuberculosis

Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tuberculosisinfection by novel vaccines would provide the most cost-effective approach to achieve the goals of the WHO End TB strategy and the Sustainable Development Goals of the United Nations. While there are few promising TB vaccine candidates available, innovation by new platforms and strategies is needed to ensure that the most effective and affordable vaccines are developed. TBVACHORIZON will innovate and diversify the global TB vaccine pipeline by pursuing four objectives: 1. Define the composition, spatial organisation and functioning of protective immune responses in the Mycobacterium tuberculosis-infected lung. 2. Evaluate whether mucosal revaccination with BCG and other live attenuated vaccines improves protective efficacy against tuberculosis infection in mice, non-human primates and humans. 3. Identify host immune response profiles and biomarkers of natural and vaccine-induced immune protection in the lung. 4. Support next generation TB vaccine development by standardised head-to-head testing of selected vaccine candidates in animals and the establishment of novel delivery systems, adjuvant formulations and GMP platforms for live attenuated vaccines. TBVACHORIZON will increase our understanding and develop tools pertaining to immune protection in the lung, the major site of tuberculosis infection. This knowledge will be exploited to develop mucosal strategies for translating towards clinical evaluation and possible implementation. The interwoven activities will consolidate Europe’s leading role in TB vaccine research and innovation, with the ultimate goal of accelerated availability of affordable, accessible and more effective TB vaccines.

结核病（TB）仍然是全球最具破坏性的传染病之一，每天造成4,000多人丧生。通过新型疫苗预防结核病会导致，将提供最具成本效益的方法来实现WHO END结核病战略的目标和联合国可持续发展目标。尽管有希望的结核病疫苗候选者很少，但需要新的平台和策略创新，以确保开发最有效，最负担得起的疫苗。 TBVACHORIZON将通过追求四个目标来创新和多样化全球结核病疫苗管道：1。定义在结核病感染的肺结核中，保护受保护的免疫复杂的组成，空间组织和功能。 2。评估BCG和其他活疫苗的粘膜重新接种是否可以提高针对小鼠，非人类灵长类动物和人类结核病感染的保护效率。 3。识别自然和疫苗诱导的肺部免疫保护的宿主免疫响应特征和生物标志物。 4。通过标准化动物中选定疫苗候选者的标准化头对头测试以及建立新型输送系统，可调节配方和GMP平台，以支持下一代结核病疫苗的开发。 Tbvachorizo​​n将增加我们的理解和开发与肺部的免疫保护有关的工具，该工具是结核病感染的主要部位。将探索这些知识以制定粘膜策略，以转化临床评估和可能的实施。交织的活动将巩固欧洲在结核病疫苗研究和创新中的领先作用，最终的目的是加速可负担，可及且更有效的结核病疫苗。